



Thomas Jefferson University  
Jefferson Digital Commons

Division of Gastroenterology and Hepatology  
Faculty Papers

Division of Gastroenterology and Hepatology

12-1-2013

# Smooth Muscle-Specific Myosin Phosphatase Target Subunit 1 (MYPT1): An Important Piece of the Puzzle.

Satish Rattan

Thomas Jefferson University, [Satish.Rattan@jefferson.edu](mailto:Satish.Rattan@jefferson.edu)

## [Let us know how access to this document benefits you](#)

Follow this and additional works at: [http://jdc.jefferson.edu/gastro\\_hepfp](http://jdc.jefferson.edu/gastro_hepfp)

 Part of the [Medicine and Health Sciences Commons](#)

### Recommended Citation

Rattan, Satish, "Smooth Muscle-Specific Myosin Phosphatase Target Subunit 1 (MYPT1): An Important Piece of the Puzzle." (2013). *Division of Gastroenterology and Hepatology Faculty Papers*. Paper 24.

[http://jdc.jefferson.edu/gastro\\_hepfp/24](http://jdc.jefferson.edu/gastro_hepfp/24)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Gastroenterology and Hepatology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

**As submitted to:**

***Gastroenterology***

**And later published as:**

**Smooth Muscle–Specific Myosin Phosphatase Target  
Subunit 1 (MYPT1): An Important Piece of the Puzzle**

**Volume 145, Issue 6, pp. 1494-5**

**DOI: 10.1053/j.gastro.2013.07.055.**

SATISH RATTAN

Department of Medicine, Division of Gastroenterology & Hepatology, Jefferson Medical  
College, Thomas Jefferson University, Philadelphia, PA

**Grant Support:** The work was supported by Grant Number RO1DK035385 from the National Institutes of Diabetes and Digestive and Kidney Diseases, and an institutional grant from Thomas Jefferson University.

**Corresponding Author:** Dr. Satish Rattan, Professor of Medicine; 901 College, Department of Medicine, Division of Gastroenterology & Hepatology, 1025 Walnut Street, Philadelphia, PA 19107; Tel # (215) 955-5614; Fax # (215) 923-7697

**Disclosures:** Dr. Rattan has nothing to disclose

Dear Sir:

We have read with great interest a recent article by Dr. He et al. in the June issue of *Gastroenterology*.<sup>1</sup> The studies provide strong evidence in favor of the concept that smooth muscle-specific myosin phosphatase target subunit 1 (MYPT1) of myosin light chain phosphatase (MLCP) plays a critical role in the agonist-induced contraction/relaxation of the smooth muscle. This was shown in their studies using animals with knocked out MYPT1<sup>-/-</sup>. The investigators employed the Cre-*loxP* system in which they used the promoter region and exon 1 of *Mypt1* flanked by 2 *loxP* sites to establish *Mypt1*-floxed mice. These mice were crossed with SMA-Cre transgenic mice to generate smooth muscle-specific MYPT1 knockout mice (*Mypt1*<sup>SMKO</sup>).

The authors demonstrated that the phasic responses (to acetylcholine, ACh and K<sup>+</sup>-depolarization) of the jejunal and ileal smooth muscles of the mutant mice in comparison with the control mice are converted into a tonic type with sustained force. The converted responses had reduced rates of shortening velocity and relaxation because of higher levels of phospho-MLC<sub>20</sub> (p-MLC<sub>20</sub>). The authors observed no apparent abnormality in the intestinal motility in the mutant mice, although there was a definite trend towards the decrease in the intestinal transit (a predicted effect). The lack of statistical significance for the abnormal intestinal motility may have been because of the huge variability among the mutant mice reflected by 49.9 ± 13.9 SEM % transit values. The issue of intestinal motility abnormality in the *Mypt1*<sup>SMKO</sup> may be resolved by studying a larger number of animals with a group beyond 16-week old, and by detailed examinations of the entire gut from the esophagus to the anorectum. The present studies had primarily focused on the limited regions of the gastrointestinal tract.

Critical role of MYPT1 in the sustained contraction has been previously demonstrated in the phenotypically tonic vs. the phasic smooth muscles of the gastrointestinal tract, in the basal state.<sup>2,3</sup> Additionally, there appear to be certain similarities between *Mypt1*<sup>SMKO</sup> animals and the spontaneously hypertensive rats: an increase in blood pressure and in the intestinal smooth muscle contractility with a corresponding decrease in MYPT1.<sup>1,4,5</sup> An increase in the neurotransmitter (ACh)-mediated amplitude and sustained contraction of the intestinal smooth muscle in MYPT1<sup>SMKO</sup> is suggestive of dysfunctional smooth muscle typified in the diffuse esophageal spasm in response to swallowing. It has been proposed that defective inhibitory neurotransmission mediated by nitric oxide (NO) and vasoactive intestinal polypeptide (VIP), unopposed excitatory neurotransmitters' (ACh; substance P, SP) contractile actions, and increased smooth muscle sensitivity may be responsible for the uncoordinated often hypertensive contractions, failure of the descending inhibition, and achalasic/hypertensive sphincteric smooth muscles.<sup>6</sup>

Present data with the higher sensitivity of the smooth muscle in response to the excitatory agonists in the presence of similar concentrations of intracellular Ca<sup>2+</sup>, suggest the role of Ca<sup>2+</sup> sensitization via inhibition of MLCP via MYPT1, the primary target for RhoA/ROCK. Also, there are studies to show significantly higher levels of endogenous inhibitory protein CPI-17 (originally named so because of its targeting PKC, protein-kinase C potentiated inhibitor) in the tonic vs. phasic smooth muscles. Recently, it is becoming evident that RhoA/ROCK contributes to Ca<sup>2+</sup> sensitization not only by targeting MYPT1 but also by targeting CPI-17, so that CPI-17 is not exclusively targeted by PKC.<sup>3,7</sup> Data from humans and animals show significantly higher levels of CPI-17 in the spontaneously tonic smooth muscle vs. the phasic, and specific decreases in the phospho-CPI-17 following selective RhoA/ROCK inhibitors. The bimodal effect of

RhoA/ROCK on MYPT1 and CPI-17 however was not appropriately discussed in the paper by He et al.

In view of a critical role of MLCK/MYPT1-MLCP/p-MLC<sub>20</sub> in the smooth muscle relaxation/contraction, it is important to determine the significance of MYPT1 in the region-specific pathophysiology in response to the corresponding reflexes, e.g. swallowing in the case of esophagus, and rectoanal inhibitory (defecation) reflex in the anorectum. In this regard, the potential of MYPT1 gene-deleted animal models similar to that of *Mypt1*<sup>SMKO</sup> (but without compensatory genetic and adaptive physiologic responses) may go beyond the investigation of the molecular mechanisms for the agonist-induced smooth muscle contraction. Such molecular insights may further reveal the pathophysiology of certain motility disorders, with or without characteristic dysfunctional inhibitory and excitatory neurotransmissions as discussed before.<sup>6</sup> These disorders may involve MYPT1-associated deranged signal transduction cascade for the smooth muscle contraction/relaxation to explain disturbed changes in the latency gradient for the sequential contractions, a hall mark for the normal progression of the food and ingesta leading to the expulsion of the waste.<sup>8</sup>

## References

1. He W-Q, et al. *Gastroenterology* 2013;144:1456-1465.
2. Rattan S, et al. *Gastroenterology* 2010;138:13-18.
3. Patel CA, et al. *Am J Physiol Gastrointest Liver Physiol* 2006;291:G830-G837.
4. De Godoy MAF, et al. *J Pharmacol Exp Ther* 2006;318:725-734.
5. De Godoy MA, et al. *Gastroenterology* 2013;143:A.
6. Goyal RK, et al. *Gastroenterology* 2010;139:1086-1090.
7. Rattan S, et al. *Am J Physiol Gastrointest Liver Physiol* 2012;302:G664-G675.
8. Sanders KM, et al. *Nat Rev Gastroenterol Hepatol* 2012;9:633-645.